Sofinnova Partners raised €650 million (~$750 million) for its Capital XI flagship fund, exceeding targets and earmarking capital for early‑stage therapeutics and medtech investments. Partners said the fund will support companies from discovery through clinic, providing longer runways and operational support amid tighter public markets. The close joins recent European VC activity, including Medicxi’s €500 million raise, and signals renewed LP appetite for life sciences earlier in the value chain. Sofinnova emphasized hands‑on support and the ability to follow through multiple financing rounds for portfolio companies.